breast cancer – media

Novartis’s Alpelisib Treats Advanced Breast Cancer

Finding the ultimate treatment for breast cancer is still a dream for all the pharma companies worldwide. At present, only hormonal therapy, Pfizer’s Ibrance, Eli Lilly’s Verzenio and Novartis’s Kisqali are available for breast cancer treatment.
- Source: Reuters
- 891
- August 24, 2018
breast cancer Company Insight Novartis
Two Approvals for AstraZeneca in Japan

The immunotherapy drug was approved for lung cancer patients with no chance for surgery whose cancer had not yet spread to other parts of the body.
- Source: Reuters
- 998
- July 3, 2018
breast cancer Japan lung cancer New Approvals
Night Shifts could Potentially Increases the Risk of Breast Cancer

More than 2.5 million people work night-shifts. In 2007, the International Agency for Research on Cancer (IARC) reported that working shifts generally disturbs momentum classified as being “probably carcinogenic to humans”.
- Source: MedicalNewsBulletin
- 790
- July 2, 2018
breast cancer cancer Researches
Error in Breast Cancer Screening

A shocking report revealed that an error in breast cancer screening tests may have affected a vast number of women across England. Due to a computer algorithm failure dating back to 2009, a group of women was not sent for routine breast cancer screening tests before their 71st birthdays. Public Health England (PHE) predicted that around 450,000 women may have been affected due to these screening errors during 2009.
- Source: DigitalHealth
- 867
- June 29, 2018
breast cancer Market Views
Canadian Scientists Find Blocking Certain Proteins can Avert Breast Cancer

Breast Cancer appears when unusual cells start growing in breast tissue and can affect both women and men. It was estimated that in the U.S. alone there will be a total of 330,080 new cases of breast cancer in women and about 2,550 in men by the end of 2018.
- Source: MedPageToday
- 829
- June 21, 2018
breast cancer Researches
Blood Test to Predict Drug Activity Against Breast Cancer

At present, breast cancer patients need to wait for nearly two to three months to find out via a scan whether palbociclib is working. This new test could detect the circulating tumor DNA which enters the bloodstream. By measuring and comparing PIK3CA levels in a blood test before and 15 post palbociclib therapy, one could predict the effectiveness of the drug.
- Source: Ddu
- 886
- June 7, 2018
blood test breast cancer Researches
Osteoporosis Drug against Breast Cancer

The amazing discovery under the authorship of Professor Chenfang Dong from the Zhejiang University School of Medicine in Hangzhou, China revealed that the widely used osteoporosis drug named zoledronic acid, inhibits UGT8 activity directly, which led to the prevention of basal-like breast cancer.
- Source: Ddu
- 891
- May 23, 2018
breast cancer Researches
Breast Cancer Diagnosis Using a Pill

A research team at the University of Michigan were developing a pill which shows the presence of tumors when exposed to infrared light, and their concept worked well in mice.
- Source: Ddu
- 802
- May 21, 2018
breast cancer cancer Researches
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 876
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System™ (ADAPT) significantly out-performed standard HER2 testing in predicting response to trastuzumab (Herceptin®) for breast cancer patients.
- Source: Carislifesciences
- 845
- March 27, 2018
breast cancer Researches trastuzumab

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.